Cantor Fitzgerald Reiterates “Overweight” Rating for Johnson & Johnson (NYSE:JNJ)

Cantor Fitzgerald reaffirmed their overweight rating on shares of Johnson & Johnson (NYSE:JNJ) in a research report report published on Monday morning, Benzinga reports. Cantor Fitzgerald currently has a $215.00 price target on the stock.

JNJ has been the topic of a number of other research reports. TD Cowen decreased their target price on Johnson & Johnson from $195.00 to $185.00 and set a buy rating on the stock in a research report on Thursday, July 18th. Daiwa America cut Johnson & Johnson from a strong-buy rating to a hold rating in a report on Tuesday, July 23rd. The Goldman Sachs Group reduced their target price on Johnson & Johnson from $160.00 to $155.00 and set a neutral rating on the stock in a report on Friday, July 19th. StockNews.com upgraded Johnson & Johnson from a buy rating to a strong-buy rating in a report on Saturday, September 14th. Finally, TD Securities reduced their target price on Johnson & Johnson from $195.00 to $185.00 in a report on Thursday, July 18th. Seven analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of Moderate Buy and a consensus price target of $173.21.

Johnson & Johnson Stock Down 0.8 %

JNJ opened at $164.82 on Monday. Johnson & Johnson has a fifty-two week low of $143.13 and a fifty-two week high of $168.85. The company has a debt-to-equity ratio of 0.44, a quick ratio of 0.85 and a current ratio of 1.07. The company has a market capitalization of $396.67 billion, a P/E ratio of 10.28, a P/E/G ratio of 2.71 and a beta of 0.53. The stock has a fifty day moving average of $161.02 and a 200-day moving average of $154.17.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings results on Wednesday, July 17th. The company reported $2.82 EPS for the quarter, beating analysts’ consensus estimates of $2.71 by $0.11. The business had revenue of $22.45 billion during the quarter, compared to the consensus estimate of $22.33 billion. Johnson & Johnson had a return on equity of 36.60% and a net margin of 46.34%. Johnson & Johnson’s revenue for the quarter was up 4.3% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $2.80 earnings per share. On average, equities analysts expect that Johnson & Johnson will post 10.02 EPS for the current year.

Johnson & Johnson Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Tuesday, September 10th. Stockholders of record on Tuesday, August 27th were given a dividend of $1.24 per share. This represents a $4.96 dividend on an annualized basis and a dividend yield of 3.01%. The ex-dividend date was Tuesday, August 27th. Johnson & Johnson’s payout ratio is 30.92%.

Insider Transactions at Johnson & Johnson

In other news, VP Robert J. Decker sold 5,635 shares of the company’s stock in a transaction that occurred on Friday, August 30th. The stock was sold at an average price of $165.06, for a total transaction of $930,113.10. Following the transaction, the vice president now directly owns 18,973 shares of the company’s stock, valued at $3,131,683.38. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 0.16% of the stock is owned by insiders.

Hedge Funds Weigh In On Johnson & Johnson

A number of institutional investors have recently modified their holdings of JNJ. Innealta Capital LLC bought a new stake in Johnson & Johnson during the second quarter worth $27,000. Christopher J. Hasenberg Inc bought a new stake in Johnson & Johnson during the first quarter worth $31,000. MFA Wealth Advisors LLC bought a new stake in Johnson & Johnson during the second quarter worth $43,000. Vermillion & White Wealth Management Group LLC bought a new stake in Johnson & Johnson during the fourth quarter worth $44,000. Finally, Fairfield Financial Advisors LTD bought a new stake in Johnson & Johnson during the second quarter worth $46,000. 69.55% of the stock is owned by institutional investors and hedge funds.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.